Cybin Inc.
A Canadian clinical-stage biopharmaceutical company developing psychedelic-based therapies for mental health conditions such as depression and anxiety. It engineers lab-modified versions of naturally occurring compounds, including psilocybin—the mushroom molecule behind the company's name. Founded in 2019, the firm later rebranded as Helus Pharma, pronounced "heal us."
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Sirenia Capital Management LP | 13G/APassive | 4.8% | 3.03M | Aug 14, 2026 |
| Alex Silverstein | 13G/APassive | 4.8% | 3.03M | Aug 14, 2026 |
| Adage Capital Management, L.P. | 13GPassive | 5.29% | 3.29M | Aug 12, 2026 |
| Robert Atchinson | 13GPassive | 5.29% | 3.29M | Aug 12, 2026 |
| Phillip Gross | 13GPassive | 5.29% | 3.29M | Aug 12, 2026 |
| Point72 Asset Management, L.P. | 13G/APassive | 1.4% | 686.7K | May 15, 2026 |
| Point72 Capital Advisors, Inc. | 13G/APassive | 1.4% | 686.7K | May 15, 2026 |
| Steven A. Cohen | 13G/APassive | 1.4% | 686.7K | May 15, 2026 |
| Millennium Management LLC | 13G/APassive | 5.7% | 2.83M | Apr 22, 2026 |
| Millennium Group Management LLC | 13G/APassive | 5.7% | 2.83M | Apr 22, 2026 |